Abstract
Conversion therapy practices (CTPs) are discredited efforts that target lesbian, gay, bisexual, trans, queer, Two-Spirit, or other (LGBTQ2S+) people and seek to change, deny, or discourage their sexual orientation, gender identity, and/or gender expression. This study aims to investigate the prevalence of CTPs across Canadian provinces and territories and identify whether CTP bans are associated with decreasing prevalence. We analyzed 119 CTPs reported from 31 adults (18+) in Canada who have direct experience with CTPs, know people who have gone to CTPs, or know of conversion therapy practitioners by using a 2020 anonymous online survey. Mapping analysis was conducted using ArcGIS Online. CTP prevalence was compared between provinces/territories with and without bans using chi-square tests. We found 3 provinces and 11 municipalities had CTP bans. The prevalence of CTPs in provinces/territories with a ban is 2.34 per 1,000,000 population (95% CI 1.65, 3.31). The prevalence of CTPs in provinces/territories without a ban is 4.13 per 1,000,000 population (95% CI 3.32, 5.14). Accounting for the underlying population, provinces/territories with the highest prevalence of CTPs are New Brunswick (6.69), Nova Scotia (6.50), and Saskatchewan (6.37). Findings suggest only 55% of Canadians are protected under CTP bans. The prevalence of CTPs in provinces/territories without a ban is 1.76 times greater than in provinces/territories with a ban. CTPs are occurring in most provinces/territories, with higher prevalence in the west and the Atlantic. Findings will help inform policymakers and legislators as they are increasingly acknowledging CTPs as a threat to the health and well-being of LGBTQ2S+ people.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Canadian Institutes of Health Research (FRN: PCS - 168193), Andrew Beckerman, and the Victoria Foundation. The funding sources did not play a role in the study design, the collection and analysis of data, the decision to publish or the preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol for this study was approved by the Simon Fraser University Research Ethics Board (study 2019s0394).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵& These authors helped draft the work and approved it for the final version to be published.
Data Availability
Data cannot be shared publicly because it contains sensitive geographic data. Data are available from the Simon Fraser University Vault and Simon Fraser Research Ethics Board (contact via dore@sfu.ca) for researchers who meet the criteria for access to confidential data.